Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

Schiffer, Charles A
Cortes, Jorge E
Hochhaus, Andreas
Saglio, Giuseppe
le Coutre, Philipp
Porkka, Kimmo
Mustjoki, Satu
Mohamed, Hesham
Shah, Neil P

May 2016

BackgroundThe proliferation of clonal cytotoxic T-cells or natural killer cells has been observed af...

Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia

Serpa, Mariana
Sanabani, Sabri S.
Dorlhiac-Llacer, Pedro Enrique
Nardinelli, Luciana
Ferreira, Patricia de Barros
Borges Martins, Thays Fernanda
Seguro, Fernanda
Bendit, Israel

January 2012

Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond...

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik
Stenke, Leif
Söderlund, Stina
Dreimane, Arta
Ehrencrona, Hans
Gedde-Dahl, Thobias
Gjertsen, Bjørn Tore
Höglund, Martin
Koskenvesa, Perttu
Lotfi, Kourosh
Majeed, Mohammed Waleed
Markevärn, Berit
Ohm, Lotta
Olsson-Strömberg, Ulla
Remes, Kari
Suominen, Merja
Simonsson, Bengt
Porkka, Kimmo
Mustjoki, Satu
Richter, Johan

December 2015

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive ...

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

July 2015

none17noneHochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ;Facon T; Goldber...

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Guilhot, F
Apperley, J
Kim, DW
Bullorsky, EO
Baccarani, M
Roboz, GJ
Amadori, S
de Souza, CA
Lipton, JH
Hochhaus, A
Heim, D
Larson, RA
Branford, S
Muller, MC
Agarwal, P
Gollerkeri, A
Talpaz, M

November 2015

Treatment options are limited for patients with imatinib-resistant or -intolerant accelerated phase ...

Efficacy and Safety of Dasatinib in Imatinib-Resistant or -Intolerant Patients with Chronic Myeloid Leukemia in Blast Phase

唐季祿
Cortes, J

May 2011

Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or ...

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

Cortes J
Kim DW
Raffoux E
Ritchie E
Roy L
Coutre S
Corm S
Hamerschlak N
Tang JL
Hochhaus A
Khoury HJ
Brümmendorf TH
Michallet M
Rege Cambrin G
Gambacorti Passerini C
Radich JP
Ernst T
Zhu C
Van Tornout JM
Talpaz M.
MARTINELLI, GIOVANNI

January 2008

Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or ...

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Apperley, J.
Cortes, J.
Kim, D.
Roy, L.
Roboz, G.
Rosti, G.
Bullorsky, E.
Abruzzese, E.
Hochhaus, A.
Heim, D.
De Souza, C.
Larson, R.
Lipton, J.
Khoury, J.
Kim, H.
Sillaber, C.
Hughes, T.
Erben, P.
Tornout, J.
Stone, R.

January 2009

PURPOSE Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant o...

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.

Visani G
Breccia M
Gozzini A
Specchia G
Montefusco E
Morra E
Annunziata M
Camera A
Cavazzini F
Stagno F
Pregno P
Usala E
Santini V
Piccaluga PP
Isidori A

January 2010

Dasatinib is effective for the treatment of chronic myeloid leukemia (CML) patients resistant or int...

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik
Stenke, Leif
Söderlund, Stina
Dreimane, Arta
Ehrencrona, Hans
Gedde-Dahl, Tobias
Tore Gjertsen, Bjorn
Hoglund, Martin
Koskenvesa, Perttu
Lotfi, Kourosh
Majeed, Waleed
Markevarn, Berit
Ohm, Lotta
Olsson-Stromberg, Ulla
Remes, Kari
Suominen, Merja
Simonsson, Bengt
Porkka, Kimmo
Mustjoki, Satu
Richter, Johan

January 2015

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive ...

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

Hochhaus, A.
Muller, M.
Radich, J.
Branford, S.
Kantarjian, H.
Hanfstein, B.
Rousselot, P.
Kim, D.
Lipton, J.
Bleickhardt, E.
Lambert, A.
Hughes, T.

January 2009

Dasatinib is a highly potent BCR–ABL inhibitor that has shown durable efficacy in patients with chro...

(NordCML006)

Henrik Hjorth-hansen
Leif Stenke
Arta Dreimane
Hans Ehrencrona
Bjørn Tore Gjertsen
Perttu Koskenvesa
Kourosh Lotfi
Waleed Majeed
Lotta Ohm
Kari Remes
Bengt Simonsson
Kimmo Porkka
Satu Mustjoki
Johan Richter
For The

August 2016

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in c...

Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia

TECCHIO, Cristina
TODESCHINI, Giuseppe
PIZZOLO, Giovanni
AMBROSETTI, Achille
Nichele I

January 2009

Dasatinib, a second-generation Abl inhibitor developed to overcome imatinib resistance in chronic my...

CLINICAL TRIALS AND OBSERVATIONS Brief report

Moshe Talpaz
Jorge Cortes

October 2016

Developing strategies to counteract ima-tinib resistance constitutes a challenge in chronic myelogen...

● ● ● CLINICAL TRIALS ANDOBSERVATIONS Comment on Cortes et al, page 3207 Unraveling CML phase by phase

September 2016

Dasatinib induces hematologic and cytogenetic responses in bothmyeloid and lym-phoid blastic phase o...

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

Schiffer, Charles A
Cortes, Jorge E
Hochhaus, Andreas
Saglio, Giuseppe
le Coutre, Philipp
Porkka, Kimmo
Mustjoki, Satu
Mohamed, Hesham
Shah, Neil P

May 2016

BackgroundThe proliferation of clonal cytotoxic T-cells or natural killer cells has been observed af...

Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia

Serpa, Mariana
Sanabani, Sabri S.
Dorlhiac-Llacer, Pedro Enrique
Nardinelli, Luciana
Ferreira, Patricia de Barros
Borges Martins, Thays Fernanda
Seguro, Fernanda
Bendit, Israel

January 2012

Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond...

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik
Stenke, Leif
Söderlund, Stina
Dreimane, Arta
Ehrencrona, Hans
Gedde-Dahl, Thobias
Gjertsen, Bjørn Tore
Höglund, Martin
Koskenvesa, Perttu
Lotfi, Kourosh
Majeed, Mohammed Waleed
Markevärn, Berit
Ohm, Lotta
Olsson-Strömberg, Ulla
Remes, Kari
Suominen, Merja
Simonsson, Bengt
Porkka, Kimmo
Mustjoki, Satu
Richter, Johan

December 2015

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive ...

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

July 2015

none17noneHochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ;Facon T; Goldber...

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Guilhot, F
Apperley, J
Kim, DW
Bullorsky, EO
Baccarani, M
Roboz, GJ
Amadori, S
de Souza, CA
Lipton, JH
Hochhaus, A
Heim, D
Larson, RA
Branford, S
Muller, MC
Agarwal, P
Gollerkeri, A
Talpaz, M

November 2015

Treatment options are limited for patients with imatinib-resistant or -intolerant accelerated phase ...

Efficacy and Safety of Dasatinib in Imatinib-Resistant or -Intolerant Patients with Chronic Myeloid Leukemia in Blast Phase

唐季祿
Cortes, J

May 2011

Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or ...

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

Cortes J
Kim DW
Raffoux E
Ritchie E
Roy L
Coutre S
Corm S
Hamerschlak N
Tang JL
Hochhaus A
Khoury HJ
Brümmendorf TH
Michallet M
Rege Cambrin G
Gambacorti Passerini C
Radich JP
Ernst T
Zhu C
Van Tornout JM
Talpaz M.
MARTINELLI, GIOVANNI

January 2008

Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or ...

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Apperley, J.
Cortes, J.
Kim, D.
Roy, L.
Roboz, G.
Rosti, G.
Bullorsky, E.
Abruzzese, E.
Hochhaus, A.
Heim, D.
De Souza, C.
Larson, R.
Lipton, J.
Khoury, J.
Kim, H.
Sillaber, C.
Hughes, T.
Erben, P.
Tornout, J.
Stone, R.

January 2009

PURPOSE Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant o...

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.

Visani G
Breccia M
Gozzini A
Specchia G
Montefusco E
Morra E
Annunziata M
Camera A
Cavazzini F
Stagno F
Pregno P
Usala E
Santini V
Piccaluga PP
Isidori A

January 2010

Dasatinib is effective for the treatment of chronic myeloid leukemia (CML) patients resistant or int...

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik
Stenke, Leif
Söderlund, Stina
Dreimane, Arta
Ehrencrona, Hans
Gedde-Dahl, Tobias
Tore Gjertsen, Bjorn
Hoglund, Martin
Koskenvesa, Perttu
Lotfi, Kourosh
Majeed, Waleed
Markevarn, Berit
Ohm, Lotta
Olsson-Stromberg, Ulla
Remes, Kari
Suominen, Merja
Simonsson, Bengt
Porkka, Kimmo
Mustjoki, Satu
Richter, Johan

January 2015

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive ...

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

Hochhaus, A.
Muller, M.
Radich, J.
Branford, S.
Kantarjian, H.
Hanfstein, B.
Rousselot, P.
Kim, D.
Lipton, J.
Bleickhardt, E.
Lambert, A.
Hughes, T.

January 2009

Dasatinib is a highly potent BCR–ABL inhibitor that has shown durable efficacy in patients with chro...

(NordCML006)

Henrik Hjorth-hansen
Leif Stenke
Arta Dreimane
Hans Ehrencrona
Bjørn Tore Gjertsen
Perttu Koskenvesa
Kourosh Lotfi
Waleed Majeed
Lotta Ohm
Kari Remes
Bengt Simonsson
Kimmo Porkka
Satu Mustjoki
Johan Richter
For The

August 2016

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in c...

Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia

TECCHIO, Cristina
TODESCHINI, Giuseppe
PIZZOLO, Giovanni
AMBROSETTI, Achille
Nichele I

January 2009

Dasatinib, a second-generation Abl inhibitor developed to overcome imatinib resistance in chronic my...

CLINICAL TRIALS AND OBSERVATIONS Brief report

Moshe Talpaz
Jorge Cortes

October 2016

Developing strategies to counteract ima-tinib resistance constitutes a challenge in chronic myelogen...

● ● ● CLINICAL TRIALS ANDOBSERVATIONS Comment on Cortes et al, page 3207 Unraveling CML phase by phase

September 2016

Dasatinib induces hematologic and cytogenetic responses in bothmyeloid and lym-phoid blastic phase o...

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

Schiffer, Charles A
Cortes, Jorge E
Hochhaus, Andreas
Saglio, Giuseppe
le Coutre, Philipp
Porkka, Kimmo
Mustjoki, Satu
Mohamed, Hesham
Shah, Neil P

May 2016

BackgroundThe proliferation of clonal cytotoxic T-cells or natural killer cells has been observed af...

Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia

Serpa, Mariana
Sanabani, Sabri S.
Dorlhiac-Llacer, Pedro Enrique
Nardinelli, Luciana
Ferreira, Patricia de Barros
Borges Martins, Thays Fernanda
Seguro, Fernanda
Bendit, Israel

January 2012

Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond...

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik
Stenke, Leif
Söderlund, Stina
Dreimane, Arta
Ehrencrona, Hans
Gedde-Dahl, Thobias
Gjertsen, Bjørn Tore
Höglund, Martin
Koskenvesa, Perttu
Lotfi, Kourosh
Majeed, Mohammed Waleed
Markevärn, Berit
Ohm, Lotta
Olsson-Strömberg, Ulla
Remes, Kari
Suominen, Merja
Simonsson, Bengt
Porkka, Kimmo
Mustjoki, Satu
Richter, Johan

December 2015

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive ...

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Abstract

Extracted data

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Abstract

Extracted data

Related items

Related items